Research News
Learn about BrightFocus-funded presentations at the 2015 Society for Neuroscience annual meeting.
Research by BrightFocus grantee Matthew Campbell, PhD, of Trinity College Dublin, represents a potential new way to help clear the brain of a build-up of the toxic amyloid beta (Aβ) that leads to Alzheimer’s.
Seven BrightFocus grantees had their research chosen as a “Hot Topic” by the ARVO Scientific Program Committee. Read about their exciting work.
Download the summer 2015 issue of our macular degeneration newsletter to learn about a new AMD treatment that is close to human clinical trials, how cataract surgery affects AMD, AREDS vitamins. risk reduction strategies for AMD, and more.
BrightFocus Foundation seeks to save sight and mind by funding innovative research worldwide and by promoting better health through education.
In an online report published April 2, 2014, BrightFocus researchers Matthew Campbell, PhD, Sarah Doyle, PhD, and Peter Humphries, PhD, and their teams, have reported from studies in mice that the inflammatory cytokine interleukin-18 (IL-18) can prevent choroidal neovascularization (CNV) formation—the fragile, leaky blood vessels forming on the retina that are the hallmark of wet AMD—and is not toxic to the retinal pigment epithelium.
